Update on Management of Type 2 Diabetes for Cardiologists
References
- American Diabetes Association Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 Jan 41 Suppl 1 S86 S104
- Garber AJ Abrahamson MJ Barzilay JI CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY Endocr Pract 2018 Jan 24 1 91 120
- American Diabetes Association Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 Jan 41 Suppl 1 S13 S27
- Bangalore S Kumar S Lobach I Messerli FH Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials Circulation 2011 Jun 21 123 24 2799 810
- Cushman WC Evans GW Byington RP ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 2010 Apr 29 362 17 1575 85
- Go AS Mozaffarian D Roger VL American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2013 update: a report from the American Heart Association Circulation 2013 Jan 1 127 1 e6 e245
- Rena G Hardie DG Pearson ER The mechanisms of action of metformin Diabetologia 2017 Sep 60 9 1577 85
- Selvin E Bolen S Yeh H Cardiovascular outcomes in trials of oral diabetes medications: a systematic review Arch Intern Med 2008 Oct 27 168 19 2070 80
- King P Peacock I Donnelly R The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes Br J Clin Pharmacol 1999 Nov 48 5 643 8
- Lamanna C Monami M Marchionni N Mannucci E Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2011 Mar 13 3 221 8
- Hirst JA Farmer AJ Ali R Roberts NW Stevens RJ Quantifying the effect of metformin treatment and dose on glycemic control Diabetes Care 2012 Feb 35 2 446 54
- Bailey CJ Day C; Metformin: its botanical background Pract Diabetes Int 2004 May 25 21 3 115 7
- Quianzon CC Cheikh IE History of current non-insulin medications for diabetes mellitus J Community Hosp Intern Med Perspect 2012 Oct 15 2 3
- Gangji AS Cukierman T Gerstein HC Goldsmith CH Clase CM A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin Diabetes Care 2007 Feb 30 2 389 94
- Monami M Genovese S Mannucci E Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2013 Oct 15 10 938 53
- Varvaki Rados D Catani Pinto L Reck Remonti L Bauermann Leitão C Gross JL The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials PLoS Med 2016 Apr 12 13 4 e1001992
- Azoulay L Suissa S Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies Diabetes Care 2017 May 40 5 706 14
- American Diabetes Association Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 Jan 41 Suppl 1 S73 S85
- Dormandy JA Charbonnel B Eckland DJ PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 2005 Oct 8 366 9493 1279 89
- Home PD Pocock SJ Beck-Nielsen H RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 Jun 20 373 9681 2125 35
- Lincoff AM Wolski K Nicholls SJ Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 2007 Sep 12 298 10 1180 8
- Kernan WN Viscoli CM Furie KL IRIS Trial Investigators Pioglitazone after Ischemic Stroke or Transient Ischemic Attack N Engl J Med 2016 Apr 7 374 14 1321 31
- Goldberg RB Kendall DM Deeg MA GLAI Study Investigators A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 2005 Jul 28 7 1547 54
- Charbonnel B Dormandy J Erdmann E Massi-Benedetti M Skene A PROactive Study Group The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 2004 Jul 27 7 1647 53
- Standl E Theodorakis MJ Erbach M Schnell O Tuomilehto J On the potential of acarbose to reduce cardiovascular disease Cardiovasc Diabetol 2014 Apr 16 13 81
- van de Laar FA Lucassen PL Akkermans RP van de Lisdonk EH Rutten GE van Weel C Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis Diabetes Care 2005 Jan 28 1 154 63
- Chiasson JL Josse RG Gomis R Hanefeld M Karasik A Laakso M STOP-NIDDM Trail Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 2002 Jun 15 359 9323 2072 7
- Schnell O Rydén L Standl E Ceriello A D&CVD EASD Study Group Updates on cardiovascular outcome trials in diabetes Cardiovasc Diabetol 2017 Oct 11 16 1 128
- Deacon CF Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes Metab 2011 Jan 13 1 7 18
- U. S. Food & Drug Administration [Internet] Silver Spring, MD U.S. Food & Drug Administration c2018 FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin; 2016 Apr 5 [cited 2018 Jun 29]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm
- Herrmann K Zhou M Wang A de Bruin TWA Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials Clin Diabetes Endocrinol 2016 May 11 2 12
- Gerstein HC Bosch J Dagenais GR ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 Jul 26 367 4 319 28
- Joseph JJ Donner TW Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes Vasc Health Risk Manag 2015 Jan 28 11 107 16
- Marso SP McGuire DK Zinman B DEVOTE Study Group Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes N Engl J Med 2017 Aug 24 377 8 723 32
DOI: https://doi.org/10.14797/mdcj-14-4-273 | Journal eISSN: 1947-6108
Language: English
Page range: 273 - 280
Published on: Oct 1, 2018
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2018 Mohammed Qureshi, Emily Gammoh, Jawairia Shakil, Richard Robbins, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.